NMPA accepts clinical trial application for monkeypox vaccine
chinadaily.com.cn |
Updated: 2023-07-14 19:44
Share
Share - WeChat
The National Medical Products Administration (NMPA) has, on Thursday, officially accepted the clinical trial application for the replication-deficient monkeypox vaccine developed by China National Pharmaceutical Group Corporation (Sinopharm) Beijing Institute of Biological Products.
- China's national medical insurance catalog contains over 230 anticancer drugs
- Hainan island activates Level-IV emergency typhoon response
- Xi congratulates Luxembourg's Grand Duke Guillaume on enthronement
- Prison terms issued over deadly 2023 Shanxi coal company fire
- PLA Navy ships depart HKSAR after open ship events
- People spend leisure time during eight-day holiday in China
